Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06005324 · ClinicalTrials.gov registry record · Phase 1
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
A Phase 1 study of HPV-Negative Squamous Cell Carcinoma, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06005324 is a Phase 1 study of HPV-Negative Squamous Cell Carcinoma that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06005324, a Phase 1 study of HPV-Negative Squamous Cell Carcinoma, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Cetuximab
- RADIATION Standard Dose Radiation
- RADIATION Low Dose Radiation
Study Locations (1)
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06005324
The ClinicalTrials.gov registry entry for NCT06005324 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HPV-Negative Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06005324 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06005324 about?
NCT06005324 is a clinical study titled "Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer". This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.
What is the current status of trial NCT06005324?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-12-18. Estimated completion is 2026-12.
What conditions does trial NCT06005324 study?
This clinical trial studies the following conditions: HPV-Negative Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06005324?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Cetuximab (DRUG), Standard Dose Radiation (RADIATION), Low Dose Radiation (RADIATION).
Who is sponsoring clinical trial NCT06005324?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06005324 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV-Negative Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.